Roche

News

GSK, iTeos take stock after Roche's TIGIT setback

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche'

News

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste

News

Roche extends Kaiku digital monitoring partnership again

Roche has elevated a longstanding alliance with Finland's Kaiku Health focusing on digital patient monitoring and management (DPMM) to the level of a strategic partnership.

News

Roche's oral SERD giredestrant fails breast cancer trial

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme

News

CHMP backs Roche's lymphoma bispecific mosunetuzumab

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody targeting CD3 and CD20 – mosunetuzumab – after getting a positive opinion for the drug

Digital

Various connections implying a world map

The largest pharma company in Europe calls for interoperabil...

Ehab Youssef, area head of Europe North at Roche Pharmaceuticals, tells us why European countries need interoperability to ensure a more effective overall European healthcare system.

GSK, iTeos take stock after Roche's TIGIT setback

Roche's TIGIT ambitions take another blow

Roche extends Kaiku digital monitoring partnership again

Roche's oral SERD giredestrant fails breast cancer trial

CHMP backs Roche's lymphoma bispecific mosunetuzumab

The largest pharma company in Europe calls for interoperabil...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Roche

Editor's Picks